Compare ADMA Biologics Inc (ADMA) vs Equinix Inc (EQIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Equinix Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Equinix Inc trades at $1,019.99 (market cap $100.89B). The key difference: Equinix Inc is far larger — about 47.4× ADMA Biologics Inc's market cap, and Equinix Inc pays a 1.93% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EQIX | |
|---|---|---|
Market Cap | $2.13B | $100.89B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $1.12K |
52-Week Low | $7.60 | $726.09 |
Enterprise Value | $2.20B | $121.17B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Equinix (EQIX) trades at $1,022.93, up 2.09% today, with a bearish technical signal despite recent AI partnership news. The stock shows strong revenue growth to $9.22B in 2025 and a net income margin of 15.07%, but faces high valuation multiples (P/E 69.08) and negative net cash flow. Analyst consensus is strongly bullish with a $1,190 price target, though recent earnings misses and elevated debt levels pose concerns.
Outlook remains mixed: AI infrastructure demand offers growth potential, but high leverage and valuation compression risks weigh on near-term upside. Investors should balance strong institutional support against execution risks and macroeconomic headwinds affecting capital-intensive expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
